Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk

BACKGROUND: Commercial gene expression signatures of prostate cancer (PCa) prognosis were developed and validated in cohorts of predominantly European American men (EAM). Limited research exists on the value of such signatures in African American men (AAM), who have poor PCa outcomes. We explored di...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Epidemiol Biomarkers Prev
Main Authors: Creed, Jordan H., Berglund, Anders E., Rounbehler, Robert J., Awasthi, Shivanshu, Cleveland, John L., Park, Jong Y., Yamoah, Kosj, Gerke, Travis A.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7942810/
https://ncbi.nlm.nih.gov/pubmed/31757784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-19-0407
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares